Updated Figures, page-37

@tnicholl I think you are right to some degree.

Dr. Lingard's appointment and him being busy buying on market is also another short term driver.

Great thing about IME is that we already have a very solid revenue base, the majority of it being recurring long term contract revenue. With solid pipeline of further sales/contracts building.

Just wait till our own FDA approval comes through in the coming weeks/months.

Plus add new revenue stream verticals of Cardiology/Pathology that will be sold to both new business and cross sold to current radiology clients.

Plus our trials in Australia already well underway at Newcastle, NSW. Conversion there to commercial contract could happen at any time. Plus the possibility of further trial sites in Australia. Remember, Dr. Lingard is a seasoned veteran. He will have countless contacts within the Australian radiology industry. I'm sure he will win further trials/business in Australia.

Lots to like about IME.